Diageo has a great new CEO: is this the start of a share price rally?

Diageoâs (LSE: DGE) share price jumped 5% yesterday (10 November). The driver of the gain was news that the company has a new CEO. Could this be the start of a long-overdue share price rally? Letâs discuss. A top choice for CEO Diageo has appointed Dave Lewis as its new CEO. And the market is […]

GLP-1 drugs beat metformin for weight control in teens with type 2 diabetes

In youth newly diagnosed with type 2 diabetes, GLP-1–based therapies, including semaglutide and tirzepatide, achieved similar blood sugar control but significantly greater reductions in body mass index than metformin. These findings highlight the potential of high-potency GLP-1 agents as effective monotherapy options in managing obesity and glycemic control in adolescents.

Mark Cuban strongly reacts to major Medicare change

Originally a trade term, Most-Favored-Nation status aims to ensure equal treatment among trading partners. In medication pricing, its goal is that the U.S. will get the best deal available globally. Specifically, MFN prescription drug pricing ties cost in the U.S. to the lowest price paid by other wealthy nations — such as Canada, Germany, or […]

Eli Lilly cuts surprising deals with upstart biotech players

Eli Lilly stock reached a new 52-week high on Nov. 10, up 4.7% and extending a month-long rally of 16%, after the pharmaceutical giant announced two strategic deals, following the highly anticipated deal with the White House. The move underlines Eli Lilly’s ambition to expand beyond its dominant obesity and diabetes franchises and enter cutting-edge […]

Semaglutide’s MASH Benefits Extend Beyond Weight Loss

(MedPage Today) — WASHINGTON — Semaglutide (Wegovy) improved liver inflammation and fibrosis in patients with metabolic dysfunction-associated steatohepatitis (MASH) through both weight loss-related and direct biological effects, according…

More of Its Money and a Little Help from Washington: How Pfizer Won Metsera

Pfizer has won the week-long bidding war for Metsera with an upwardly revised up-to-$10 billion offer matching that of rival Novo Nordisk—and more than a little help from Washington. Novo Nordisk has given up on trying to outbid Pfizer to acquire the obesity and metabolic drug developer after one-upping the pharma giant last week. Metsera […]